Showing 2644 results
- Media Release /Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers…
- Pulse Update /
- Media Release /The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of…
- Featured News /
Novartis announced the company’s financial results for the first quarter of 2023.
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core…
- Key Release /Annonce événementielle au sens de l’art. 53 RC Au T1, chiffre d’affaires en hausse de +8% (tcc1, +3% USD) et du résultat opérationnel de +15% (tcc, +8% USD) Innovative Medicines (IM): hausse de +…
- Media Library /
- Story /
An essay by Vas Narasimhan, CEO of Novartis about the historical context and coming innovations in medicine with an introduction by Goran Mijuk.
- Media Release /Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for…
Pagination
- ‹ Previous page
- 1
- …
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- …
- 265
- › Next page